One Reason Novartis is Expected to Overtake Pfizer in Revenue: its Generics Business
A study by EvaluatePharma.com projects Novartis (NVS) will overtake Pfizer (PFE) to become the leading drug maker by revenue by 2018, and one reason is the robust generics operation of Novartis.
Sanofi (SNY) and GlaxoSmithKline (GSK) trail close behind.
NVS Revenue TTM data by YCharts
As Bloomberg reported, Novartis, through a combination of continuing brand sales and by developing its own generic to compete with the branded drug Diovan ($5.7 billion in sales last year), has thus far, in the initial months of Diovan going generic, held onto more than half of sales for the drug.
The generic version is marketed by Novartis’s Sandoz unit. Cannibalizing your own revenue with a generic version of the drug, surely beats having someone cannibalize it for you, eh?
Jeff Bailey is the editor of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.
Filed under: Company Analysis
Search Articles
Subscribe to YCharts Analysis
